Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ochi A"'
Autor:
Yoichi Shimizu, Eisuke Ochi, Hiroji Iwata, Noriatsu Tatematsu, Taichi Shimazu, Yutaka Matsuoka, Naomi Sakurai, Ryo Okubo, Katsunori Tsuji
Publikováno v:
Cancer Research. 80:P6-11
[Backgrounds] Many breast cancer survivors (BCSs) still remain physically inactive. Lack of receiving physical activity (PA) information from oncology care providers (OCPs) is known as one of patient-reported barriers to get exercise habits. [Methods
Autor:
Aya Kuchiba, Taro Ueno, Ryo Okubo, Taichi Shimazu, Naomi Sakurai, Takayuki Kinoshita, Katsunori Tsuji, Yutaka Matsuoka, Yuri Ishino, Yoichi Shimizu, Eisuke Ochi, Tomomi Narisawa
Publikováno v:
Cancer Research. 80:OT3-12
Maintaining high levels of physical activity not only helps to maintain and improve physical health and quality of life, but also plays a role in reducing adverse effects due to cancer treatments. Moreover, a greater degree of cardiorespiratory fitne
Autor:
Takayuki Iwamoto, B Giampaolo, D Kobayashi, Koyu Suzuki, F Nozaki, Hideko Yamauchi, M Murai, Norio Hayashi, T Ochi, Naoki Niikura
Publikováno v:
Cancer Research. 79:P2-08
Background: Lymphocyte predominant breast cancer subgroup, defined as ≥ 50% stromal tumor-infiltrating lymphocytes (sTILs), is associated with high pathological complete response (pCR) rate after neoadjuvant therapy (NAT) and favorable outcome. In
Autor:
Masakazu Toi, Kenichi Yoshida, Satoru Miyano, Seishi Ogawa, Tatsuki R. Kataoka, Masahiro Hirata, Yasuhide Takeuchi, Yotaro Ochi, Yusuke Shiozawa, Kosuke Aoki, Hirona Maeda, Satoko Baba, Takaki Sakurai, Masahiro Nakagawa, Kenichi Chiba, Kengo Takeuchi, Yukiko Kawata, Tomomi Nishimura, Yuichi Shiraishi, Nobuyuki Kakiuchi, Hironori Haga
Publikováno v:
Cancer Research. 80:P4-05
[Introduction] Proliferative lesions in the breast have been implicated in the development of invasive breast cancer. Previous studies showed that atypical proliferative lesions and adjacent breast cancers shared common genetic alterations, suggestin
Autor:
Hiroshi Shiku, Kiyotaka Kuzushima, Takashi Sugiyama, Fumihiro Ochi, Nicholas Casey, Hiroshi Fujiwara, A. John Barrett, Hiroki Tanaka, Junichi Mineno, Masaki Yasukawa, Kazushi Tanimoto, Sachiko Okamoto
Publikováno v:
Clinical Cancer Research. 22:4405-4416
Purpose: Mogamulizumab (Mog), a humanized anti-CC chemokine receptor 4 (CCR4) mAb that mediates antibody-dependent cellular cytotoxicity (ADCC) using FcγR IIIa (CD16)-expressing effector cells, has recently been approved for treatment of CCR4-positi
Autor:
Claire Leppold, Hiromichi Ohira, Tomohiro Morita, Masaharu Tsubokura, Manabu Tsukada, Shuhei Nomura, M Kami, Shigehira Saji, Tetsuya Tanimoto, S Ochi, A Ozaki, S Kato, T Yokota
Publikováno v:
Cancer Research. 76:P6-12
Introduction In breast cancer, delay in first presentation and self-interruption of continuous treatment are associated with lower survival. It has been suggested that risk factors for such behavioral patterns include poor social support. Minamisoma
Autor:
Hiroshi Fujiwara, Yuki Yamashita, Tingxi Guo, Munehide Nakatsugawa, Kenji Chamoto, Masaki Yasukawa, Naoto Hirano, Marcus O. Butler, Toshiki Ochi, Shinya Tanaka
Publikováno v:
Cancer Immunology Research. 3:1070-1081
Adoptive transfer of T cells redirected by a high-affinity antitumor T-cell receptor (TCR) is a promising treatment modality for cancer patients. Safety and efficacy depend on the selection of a TCR that induces minimal toxicity and elicits sufficien
Autor:
Niels Reinmuth, Lijia Wang, Alessandro Morabito, Steven L. McCune, Marcin Kowanetz, Ahad Sadiq, Helen Jessop, Hans-Georg Kopp, Michael McCleod, Tania Ochi Lohmann, Alan Sandler, Alona Zer, Davey B. Daniel, Tarek Mekhail, Maen A. Hussein, V. Archer, Achim Rittmeyer, Henry Jacob Conter, Federico Cappuzzo, Howard West
Publikováno v:
Cancer Research. 79:CT200-CT200
Background: Atezolizumab (atezo) (anti-PD-L1) monotherapy improves overall survival (OS) vs docetaxel in 2L+ NSCLC regardless of PD-L1 status; phase 3, 1L studies have shown clinical benefit of atezo plus chemotherapy and atezo in combination with be
Autor:
Hiroshi Fujiwara, Hiroaki Asai, Katsuto Takenaka, Masaki Yasukawa, Yoshihiro Yakushijin, Toshiki Ochi, Masaki Maruta, Takeshi Imamura, Kazushi Tanimoto, Takashi Saitou
Publikováno v:
Cancer Immunology Research. 7:B031-B031
Background: T-cell therapy can be a promising treatment option even in patients with refractory malignancies including myeloma. NY-ESO-1 is a well-known cancer-testis antigen which is expressed by refractory myeloma cells, and a NY-ESO-1_157-165 pept
Autor:
Kaichiro Ikebuchi, Yasuo Hisa, Hitosuke Tameno, Takuma Inui, Yasuko Ochi, Hidetoshi Okabe, Yasuhiro Furuichi, Kazunobu Futami, Tokuhiro Chano, Akihito Arai, Taketoshi Shimada
Publikováno v:
Cancer Research. 71:4598-4607
RECQL1 and WRN proteins are RecQ DNA helicases that participate in suppression of DNA hyper-recombination and repair. In this study, we report evidence supporting their candidacy as cancer therapeutic targets. In hypopharyngeal carcinomas, which have